NCT00476554

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Cyclacel Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL).

Detailed description

This is an open label, randomized phase II study designed to evaluate the tolerability and response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell lymphoma (CTCL) who have had progressive, recurrent, or persistent disease on or following 2 systemic therapies.

Conditions

• Cutaneous T-cell Lymphoma (CTCL)

Interventions

Type	Name	Description
DRUG	Sapacitabine	Sapacitabine

Timeline

• Start date: 2007-04-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2007-05-22
• Last updated: 2021-12-22

Locations

3 sites across 1 country: United States